Distribution Alliance for Dermal Allograft

A new dermal allograft for the repair of soft tissue defects such as those found in incontinent patients will be distributed by the Urological Division of C.R. Bard (Murray Hill, NJ, USA) under an agreement with Regeneration Technologies Inc. (RTI, Alachua, FL, USA). The allograft will be marketed as Bard Dermal Allograft.

The allograft, small portions of donor skin not usable for treating burn patients, is based on patent-pending soft tissue processing technology developed by RTI. It is used in pelvic floor reconstruction and repair to treat incontinence. The allograft comes in a range of sizes and is freeze-dried for convenient room-temperature storage. RTI processes the allograft using a method that helps promote fibroblast infiltration and generation of host collagen within the implant. This method creates a collagen scaffold and may have other applications in reconstructive surgery.

"Bard is a leader in urinary healthcare, delivering value-driven products and services that focus on the needs of physicians and the patients they serve,” said Jamie M. Grooms, president and CEO of RTI.



Related Links:
RTI
Bard